In a report issued on February 28, Kaveri Pohlman from BTIG assigned a Buy rating to Nuvation Bio (NUVB – Research Report), with a price target of $16.00. The company’s shares closed last Wednesday at $5.40, close to its 52-week low of $4.46.
According to TipRanks.com, Pohlman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -31.4% and a 12.1% success rate. Pohlman covers the Healthcare sector, focusing on stocks such as Sonnet BioTherapeutics Holdings, Oncternal Therapeutics, and Mersana Therapeutics.
Currently, the analyst consensus on Nuvation Bio is a Moderate Buy with an average price target of $16.00.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $15.23 and a one-year low of $4.46. Currently, Nuvation Bio has an average volume of 1.14M.
Based on the recent corporate insider activity of 9 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NUVB in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Panacea Acquisition Corp is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
Read More on NUVB:
